title: Switch from anakinra to canakinumab in a severe case of CINCA syndrome.
authors.affiliation: Institute of Pediatrics, Università Cattolica Sacro Cuore, Rome, Italy.
authors.forename: Donato
authors.initials: D
authors.lastname: Rigante
authors.affiliation: Department of Internal Medicine, Periodic Fever Research Center, Università Cattolica Sacro Cuore, Rome, Italy.
authors.forename: Elena
authors.initials: E
authors.lastname: Verrecchia
authors.affiliation: Institute of Ophthalmology, Università Cattolica Sacro Cuore, Rome, Italy.
authors.forename: Benedetto
authors.initials: B
authors.lastname: Falsini
authors.affiliation: Department of Internal Medicine, Periodic Fever Research Center, Università Cattolica Sacro Cuore, Rome, Italy.
authors.forename: Raffaele
authors.initials: R
authors.lastname: Manna
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D056587:Cryopyrin-Associated Periodic Syndromes / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D057915:Drug Substitution; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D055118:Medication Adherence; D012074:Remission Induction; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D053590:Interleukin 1 Receptor Antagonist Protein; C541220:canakinumab